Citigroup Inc Atreca, Inc. Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$1.56 - $3.25 $2,009 - $4,186
-1,288 Reduced 83.04%
263 $0
Q1 2022

May 12, 2022
SELL
$1.61 - $5.2 $8,589 - $27,742
-5,335 Reduced 77.48%
1,551 $5,000
Q4 2021

Feb 10, 2022
BUY
$2.87 - $6.29 $4,075 - $8,931
1,420 Added 25.98%
6,886 $21,000
Q3 2021

Nov 10, 2021
BUY
$4.91 - $9.07 $26,838 - $49,576
5,466 New
5,466 $34,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email